The U.S. Senate approved a new iteration of the Biosecure Act as an amendment to the National Defense Authorization Act for FY2026. The revised bill seeks to restrict federal funding or contracting with 'biotechnology companies of concern' and narrows provisions compared with prior versions that explicitly named Chinese firms; the amendment passed the Senate but must still clear House‑Senate reconciliation. Lawmakers say the measure aims to protect U.S. biosecurity and critical supply chains, while some researchers warn the bill could disrupt collaborations and access to services such as contract manufacturing and sequencing. Stakeholders across industry and academia will be watching conference committee negotiations for the final language and the list of affected entities.